Amneal Pharmaceuticals AMRX · USD

Although we had a minority economic interest in Amneal prior to March 2023, we were Amneal’s sole managing member (and we continue to be the sole managing member), having the sole voting power to make all of Amneal’s business decisions and control its management. Therefore, we consolidated the financial statements of Amneal and its subsidiaries for all periods prior to the Reorganization. We recorded non-controlling interests for the portion of Amneal’s economic interests that we did not hold prior to the Reorganization.

On May 8, 2025, we entered into a 15-year strategic collaboration agreement with ApiJect Systems, Corp. and related entities (“ApiJect”), a medical technology company focused on advanced drug delivery (“ApiJect Agreement”). Under the ApiJect Agreement, we will install and operate manufacturing equipment leased from Apiject at our Brookhaven, New York facility. This equipment will be used to support production of ApiJect’s proprietary blow fill seal (“BFS”) delivery systems and our growing injectable portfolio. We will pay a low-digit royalty to ApiJect for any of our commercial products that are manufactured utilizing the equipment. At the conclusion of the term of the ApiJect Agreement, we have the right to purchase the equipment from ApiJect for a nominal amount. We will also collaborate with ApiJect on the development of additional injectable product programs utilizing ApiJect’s BFS platform. We are entitled to receive consideration from ApiJect for development work performed under these programs.

Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗